ALK rearrangement

What it is

ALK rearrangement is a cancer-driving gene fusion, found in about 2% to 7% of non-small cell lung cancers, that can guide targeted therapy. It means the ALK (anaplastic lymphoma kinase) gene has broken and rejoined with another gene, creating an abnormal ALK fusion protein that stays switched on and pushes cancer-cell growth. In lung cancer, the best-known example is EML4-ALK, first described in 2007. This matters because a confirmed ALK rearrangement can make a patient eligible for ALK-targeted medicines rather than standard treatment alone.

Although many people hear about ALK in lung cancer, ALK fusions also occur in other tumours, including anaplastic large cell lymphoma, inflammatory myofibroblastic tumour, and some rarer cancers. The term may refer either to the biomarker itself or to ALK fusion testing, which is the lab work done on tumour tissue, and sometimes blood, to look for it.

A few points are useful to separate:

Term	What it means
ALK rearrangement	A structural change in the ALK gene that creates a fusion with another gene
ALK fusion	The abnormal hybrid gene or protein produced by that rearrangement
ALK-positive	The tumour tests positive for a clinically relevant ALK alteration
ALK fusion testing	Lab testing used to detect the rearrangement/fusion

In practice, doctors usually order ALK testing as part of molecular profiling for advanced non-squamous non-small cell lung cancer, especially lung adenocarcinoma. In India, this is commonly done in tertiary cancer centres and larger pathology labs using tissue biopsy samples, with increasing use of broad next-generation sequencing panels where available.

How it works

ALK normally encodes a receptor tyrosine kinase, a protein involved in cell signaling. When ALK becomes fused to another gene, the partner gene can force ALK into a permanently active state. That abnormal kinase then activates downstream pathways that support cell proliferation, survival, and tumour formation.

Different partner genes can fuse with ALK. In NSCLC, EML4 is the most common partner, but others such as KIF5B, KLC1, HIP1, TFG, STRN, and several more have been reported. The exact fusion partner and breakpoint can sometimes affect how strongly the protein signals, how well a test detects it, and possibly how the cancer responds to treatment, although this area is still being studied.

ALK rearrangements are considered actionable biomarkers because they identify tumours that may respond to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, brigatinib, ceritinib, and lorlatinib, depending on the cancer type, treatment line, and local approval or availability. The key idea is that the cancer may become highly dependent on ALK signaling, so blocking ALK can shrink the tumour.

Evidence and uses

The strongest clinical use of ALK rearrangement testing is in non-small cell lung cancer. In this setting, ALK-positive tumours often respond better to ALK-targeted drugs than to conventional chemotherapy alone. This is why major lung cancer guidelines include ALK testing in the work-up of advanced NSCLC, particularly adenocarcinoma.

Common clinical uses include:

1. Choosing first-line treatment in advanced NSCLC
2. Selecting later-line targeted therapy if cancer progresses
3. Clarifying diagnosis in some rare tumours such as inflammatory myofibroblastic tumour
4. Broad molecular profiling when tissue is limited or when multiple biomarkers are being checked together

Several testing methods are used:

Test method	What it detects	Strengths	Limits
Immunohistochemistry (IHC)	ALK protein overexpression	Fast, widely used, tissue-sparing	May need confirmation in some settings
FISH (fluorescence in situ hybridisation)	ALK gene rearrangement at chromosome level	Historically a reference method	More labour-intensive, costlier, harder to interpret in some samples
RT-PCR	Known fusion transcripts	Sensitive for specific fusions	Can miss uncommon or novel partners
Next-generation sequencing (NGS)	Many gene fusions and mutations at once	Broad, can identify rare partners	Cost, turnaround time, tissue quality requirements

No single method is perfect in every situation. Older practice often relied on FISH as a reference standard, while many current centres use IHC and/or NGS because they are practical and can fit into broader biomarker testing. If results are unclear, the pathology team may recommend another method on the same sample or a repeat biopsy.

ALK testing is usually done on tumour tissue from a biopsy or surgery specimen. If tissue is scarce or unsafe to re-biopsy, some centres may use liquid biopsy approaches, but tissue remains important because blood tests can miss some fusions. A negative blood test does not always rule out an ALK rearrangement.

Diagnosis / how it's measured

ALK rearrangement is not diagnosed from symptoms or scans. It is identified by a molecular pathology test on cancer cells.

Typical steps are:

1. Biopsy confirms the cancer type
2. Pathology selects tissue for biomarker testing
3. ALK is tested by IHC, FISH, NGS, or another validated method
4. Results are interpreted with the full clinical picture

The report may say things like:

• ALK positive or ALK rearrangement detected
• EML4-ALK fusion detected
• No ALK rearrangement detected
• Indeterminate / insufficient sample

An insufficient or indeterminate result does not mean the tumour is definitely ALK-negative. It may simply mean there were too few tumour cells, poor RNA quality, or technical limits. This is common when biopsy samples are very small.

In lung cancer, ALK rearrangements are more often seen in adenocarcinoma, and have been associated with younger age and never- or light-smoking history, but these are not strict rules. A person can still have an ALK fusion even if they do not fit the typical profile, so testing decisions should follow current oncology guidance rather than assumptions.

When to see a clinician

Ask your oncologist about ALK testing if you or a family member has:

• Advanced or metastatic non-small cell lung cancer, especially adenocarcinoma
• A pathology report that says molecular testing pending or insufficient tissue
• Cancer progression after initial treatment without full biomarker testing
• A rare tumour type in which ALK fusions may affect treatment choices

It is reasonable to ask specific questions such as: Was ALK tested? Which method was used? Was the sample adequate? If the result was negative, was broad NGS done or considered? In India, if testing is not available locally, oncologists may refer samples to accredited outside laboratories.

Limitations and open questions

ALK rearrangement is an important biomarker, but it has limits. Not every ALK-positive cancer responds the same way, and many tumours eventually develop resistance to ALK inhibitors through additional mutations or other escape pathways. Also, different tests can occasionally give discordant results, especially with rare fusion partners or low-quality samples.

Evidence is strongest in NSCLC and some rarer ALK-driven tumours, but less complete in many other cancers where ALK fusions are uncommon. Researchers are still studying whether specific fusion variants predict better or worse outcomes, how best to use liquid biopsy, and how to sequence newer ALK inhibitors after resistance develops.

For patients, the practical point is simple: ALK testing can change treatment options, but the result needs to be interpreted by an oncologist and pathologist together. A positive result is highly relevant, a negative result may still need context, and an inconclusive result may justify repeat or broader testing.